CDT
CDT Equity Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.63
−16.56%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
4.0x
Market Cap
$8.56M
MomentumView details →
1D Return
−16.56%
YTD Return
−99.79%
RSI (14)
20.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
4.0x
Market Cap
$8.56M
RSI (14)
20.7
MomentumView details →
1D Return
−16.56%
YTD Return
−99.79%
SummaryUpdated Jun 1, 2026
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) is a clinical-stage specialty biopharmaceutical company founded in 2019 and headquartered in San Diego, California. The company went public in March 2022 and operates as a subsidiary of Corvus Capital Limited. Conduit focuses on developing treatments for unmet medical needs in autoimmune diseases and male reproductive health, with a pipeline centered around two main drug candidates targeting conditions such as Hashimoto's thyroiditis and idiopathic male infertility.
Similar companies
Latest newsMore news →
CDT Equity Inc. issued a senior secured convertible promissory note to J.J. Astor & Co. in the principal amount of $541,620.1h agoJames Bligh was appointed Chief Executive Officer of CDT Equity Inc., effective 2026-08-31, succeeding Andrew Regan who resigned as CEO and director with severance of $50,000 per month for six months.3d agoCDT Equity Inc. announced an investment in US-based peptide company Pep'd Inc. via a SAFE note, expanding into the US peptide market.11d ago